Updated NICE Treatment Options Summary – SACT for Advanced Non-Small Cell Lung Cancer: User Feedback

In September, NICE updated its Systemic anti-cancer therapy (SACT) for advanced non small cell lung cancer: treatment options summary:
https://www.nice.org.uk/guidance/ng122/resources/interactive-pdf-of-all-treatment-pathways-for-squamous-and-nonsquamous-advanced-nonsmallcell-lung-cancer-pdf-11189888174.

The aim of this summary is to collate NICE technology appraisal (TA) and NICE guideline recommendations, and to present the recommended treatment options visually. This lung cancer product brings together these NICE recommendations in an integrated way and includes NHSE commissioning agreements reflected in blueteq forms and criteria listed on the Cancer Drugs Fund. The summary is updated to incorporate newly published TAs and is reviewed by a group of experts in the field consisting of consultant oncologists, respiratory physicians, and pharmacists, to ensure the summary reflects current clinical practice. It replaces the previous 3 visual summaries for squamous and non-squamous disease. These were flat pdf documents which were becoming both cumbersome to use and difficult for NICE to update. This new product has an interactive title page enabling users to select a pathway by biomarker, hopefully making it far easier to use, and grants us extra space to incorporate more TAs as they are approved in this fast-paced area.

NICE is currently gathering user feedback on the treatment options summary.  They would welcome any feedback via the SNAP survey at https://online1.snapsurveys.com/lungcancerpathways which is open until 5pm 30 November 2022.